An overview about the medical use of antifungals in Portugal in the last years

Azevedo, Maria Manuel; Cruz, Luisa; Pina-Vaz, Cidália; Rodrigues, Acácio Gonçalves

doi:10.1057/jphp.2016.4

Cited by 2 publications

(2 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In recent years, the emergence of azole-resistant Aspergillus strains has substantially risen in Portugal, with the use of antifungal drugs per capita increasing more than in other European countries [ 48 – 50 ]. The release of over-the-counter antifungals and the increased industry marketing have encouraged and promoted self-medication, enabling uncontrolled, inadequate, and prolonged azole utilization.…”

Section: Discussionmentioning

confidence: 99%

Multicentric Study on the Clinical Mycology Capacity and Access to Antifungal Treatment in Portugal

Fernandes,

Sabino,

Cunha

et al. 2024

Mycopathologia

View full text Add to dashboard Cite

The success of the clinical management of invasive fungal diseases (IFD) is highly dependent on suitable tools for timely and accurate diagnosis for effective treatment. An in-depth analysis of the ability of European institutions to promptly and accurately diagnose IFD was previously conducted to identify limitations and aspects to improve. Here, we evaluated and discussed the specific case of Portugal, for which, to our knowledge, there are no reports describing the national mycological diagnostic capacity and access to antifungal treatment. Data from 16 Portuguese medical institutions were collected via an online electronic case report form covering different parameters, including institution profile, self-perceived IFD incidence, target patients, diagnostic methods and reagents, and available antifungals. The majority of participating institutions (69%) reported a low-very low incidence of IFD, with Candida spp. indicated as the most relevant fungal pathogen, followed by Aspergillus spp. and Cryptococcus spp. All institutions had access to culture and microscopy, whereas 94 and 88% were able to run antigen-detection assays and molecular tests, respectively. All of the institutions capable of providing antifungal therapy declared to have access to at least one antifungal. However, echinocandins were only available at 85% of the sites. Therapeutic drug monitoring (TDM) was reported to remain a very restricted practice in Portugal, being available in 19% of the institutions, with the TDM of itraconazole and posaconazole performed in only 6% of them. Importantly, several of these resources are outsourced to external entities. Except for TDM, Portugal appears to be well-prepared concerning the overall capacity to diagnose and treat IFD. Future efforts should focus on promoting the widespread availability of TDM and improved access to multiple classes of antifungals, to further improve patient outcomes.

show abstract

Section: Discussionmentioning

confidence: 99%

Multicentric Study on the Clinical Mycology Capacity and Access to Antifungal Treatment in Portugal

Fernandes,

Sabino,

Cunha

et al. 2024

Mycopathologia

View full text Add to dashboard Cite

show abstract

“…While these numbers may be relatively small compared to other countries, the diversity of fungal species causing these infections is noteworthy[14]. This has important implications for clinical and laboratory diagnosis, and therefore therapeutic management, as different fungal species exhibit diverse patterns of susceptibility to antifungal drugs.In recent years, the emergence of azole-resistant Aspergillus strains has substantially increased in Portugal, with the Portuguese population using more antifungal drugs per capita than other European countries[54][55][56]. The liberation of over the counter (OTC) antifungals outside pharmacies and the increased pharmaceutical industry marketing has encouraged and promoted self-medication, enabling an uncontrolled, inadequate, and prolonged azole utilization.…”

mentioning

confidence: 99%

Clinical mycology capacity and access to antifungal treatment in Portugal

Fernandes,

Carvalho,

Salmanton-García

et al. 2023

Preprint

View full text Add to dashboard Cite

The success of the clinical management of invasive fungal diseases (IFD) is highly dependent on the availability of suitable tools for the timely and accurate diagnosis for effective treatment. Unfortunately, the lack of appropriate diagnostic tools remains still one major hurdle contributing to the high mortality rates associated with these infections. An in-depth analysis of the ability of European institutions to promptly and accurately diagnose IFD was previously conducted to identify limitations and aspects to improve. Here, we evaluated and discuss the specific case of Portugal, for which, to our knowledge, there are no reports describing the national mycological diagnostic capacity and access to antifungal treatments. Data from 16 Portuguese medical institutions were collected via an online electronic case report form covering different parameters, including institution profile, self-perceived IFD incidence, target patients, diagnostic methods and reagents, and available antifungals. The majority of participating institutions (69%) reported a low-very low incidence of IFD, with Candida spp. indicated as the most relevant fungal pathogen, followed by Aspergillus spp., and Cryptococcus spp. All the institutions had access to culture and microscopy, whereas 94% and 88% were able to run antigen-detection assays and molecular tests, respectively. Regarding the antifungal availability in the country, 100% of the institutions capable of providing antifungal therapy, declared to have access to at least one formulation. However, echinocandins were only available at 85% of the sites. Therapeutic drug monitoring (TDM) was reported to remain a very restricted practice in Portugal, being available in 19% of the institutions, with the TDM of itraconazole and posaconazole performed in only 6% of them. Importantly, despite some of these resources being well-represented among Portuguese institutions, most of them are outsourced to external entities. With the exception of TDM, Portugal appears to be well-prepared with regard to the overall capacity to diagnose and treat IFD. Future efforts should focus on promoting the widespread availability of TDM and improved access to multiple classes of antifungals, to further improve patient outcomes.

show abstract

An overview about the medical use of antifungals in Portugal in the last years

Cited by 2 publications

References 35 publications

Multicentric Study on the Clinical Mycology Capacity and Access to Antifungal Treatment in Portugal

Multicentric Study on the Clinical Mycology Capacity and Access to Antifungal Treatment in Portugal

Clinical mycology capacity and access to antifungal treatment in Portugal

Contact Info

Product

Resources

About